BRINSUPRI: Insmed's Landmark Drug Redefining Non-Cystic Fibrosis Bronchiectasis Treatment
For decades, non-cystic fibrosis bronchiectasis (NCFB) patients had no dedicated, FDA-approved therapy — relying instead on antibiotics, airway clearance techniques, and supportive care to manage a chronic and often debilitating condition. That changed with the arrival of brinsupri (brensocatib),...
Unlocking the Full Value of Healthcare Interventions Through HEOR
The global push toward value-based care has fundamentally altered how medical treatments are evaluated, priced, and reimbursed. Demonstrating clinical superiority alone is no longer sufficient to secure market access — economic evidence must accompany every product launch. Among the most persuasive frameworks available to...
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek